RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $305
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price target from $296 to $305.
RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price target from $296 to $305.